Current Imaging paradigms in radiation oncology

被引:48
作者
Apisarnthanarax, S
Chao, KSC
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
关键词
D O I
10.1667/RR3279
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The technological revolution in imaging during recent decades has transformed the way image-guided radiation therapy is performed. Anatomical imaging (plain radiography, computed tomography, magnetic resonance imaging) greatly improved the accuracy of delineating target structures and has formed the foundation of 3D-based radiation treatment. However, the treatment planning paradigm in radiation oncology is beginning to shift toward a more biological and molecular approach as advances in biochemistry, molecular biology, and technology have made functional imaging (positron emission tomography, nuclear magnetic resonance spectroscopy, optical imaging) of physiological processes in tumors more feasible and practical. This review provides an overview of the role of current imaging strategies in radiation oncology, with a focus on functional imaging modalities, as it relates to staging and molecular profiling (cellular proliferation, apoptosis, angiogenesis, hypoxia, receptor status) of tumors, defining radiation target volumes, and assessing therapeutic response. In addition, obstacles such as imaging-pathological validation, optimal timing of post-therapy scans, spatial and temporal evolution of tumors, and lack of clinical outcome studies are discussed that must be overcome before a new era of functional imaging-guided therapy becomes a clinical reality. (C) 2005 by Radiation Research Society.
引用
收藏
页码:1 / 25
页数:25
相关论文
共 198 条
[1]   Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer [J].
Adams, S ;
Baum, RP ;
Stuckensen, T ;
Bitter, K ;
Hör, G .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) :1255-1260
[2]   An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer [J].
Akhurst, T ;
Downey, RJ ;
Ginsberg, MS ;
Gonen, M ;
Bains, M ;
Korst, R ;
Ginsberg, RJ ;
Rusch, VW ;
Larson, SM .
ANNALS OF THORACIC SURGERY, 2002, 73 (01) :259-264
[3]  
ALAVI JB, 1988, CANCER, V62, P1074, DOI 10.1002/1097-0142(19880915)62:6<1074::AID-CNCR2820620609>3.0.CO
[4]  
2-H
[5]   METABOLISM OF HUMAN GLIOMAS - ASSESSMENT WITH H-1 MR SPECTROSCOPY AND F-18 FLUORODEOXYGLUCOSE PET [J].
ALGER, JR ;
FRANK, JA ;
BIZZI, A ;
FULHAM, MJ ;
DESOUZA, BX ;
DUHANEY, MO ;
INSCOE, SW ;
BLACK, JL ;
VANZIJL, PCM ;
MOONEN, CTW ;
DICHIRO, G .
RADIOLOGY, 1990, 177 (03) :633-641
[6]  
Ang KK, 2002, CANCER RES, V62, P7350
[7]  
ARCHER CR, 1982, LARYNGOSCOPE, V92, P1173
[8]   Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose:: Use and limitations [J].
Avril, N ;
Rosé, CA ;
Schelling, M ;
Dose, J ;
Kuhn, W ;
Bense, S ;
Weber, W ;
Ziegler, S ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3495-3502
[9]   Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose [J].
Avril, N ;
Dose, J ;
Janicke, F ;
Ziegler, S ;
Romer, W ;
Weber, W ;
Herz, M ;
Nathrath, W ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1204-1209
[10]  
Avril N, 2001, J NUCL MED, V42, P9